PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to address the following hypotheses: the PD-1 inhibitor
Sintilimab 200mg for intravenous (IV) administration will be given together with three-week
epirubincin, cyclophosphamide (EC) × 4 treatments from the second cycle followed by weekly
nab-paclitaxel x12 treatments or three-week nab-paclitaxel x4 treatments. This regimen will
induce higher pathologic complete response (pCR) rate in triple negative breast cancer than
historical pCR rates (30-40%) observed with chemotherapy alone.